Sign In
Buy IRON
$70.35
+2.35 (+3.46%)
At Close: Jun 03, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
03:12pm, Thursday, 26'th Feb 2026
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised to co
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
08:30am, Thursday, 26'th Feb 2026
WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction
03:19pm, Wednesday, 25'th Feb 2026
Hedge fund BVF added 650,000 shares of Disc Medicine in the fourth quarter. The quarter-end position value rose by $51.62 million as a result.
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst
02:51pm, Wednesday, 25'th Feb 2026
Great Point Partners acquired 250,000 shares in IRON during the fourth quarter. The quarter-end position value increased by $19.85 million due to the new investment.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
05:23pm, Tuesday, 24'th Feb 2026
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. (“Disc” or the “Company”) (NASDAQ: IRON). Such investors are
Insider Selling: Disc Medicine (NASDAQ:IRON) CFO Sells $463,593.07 in Stock
04:32am, Sunday, 22'nd Feb 2026
Disc Medicine, Inc. (NASDAQ: IRON - Get Free Report) CFO Jean Franchi sold 7,081 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $65.47
Insider Selling: Disc Medicine (NASDAQ:IRON) CEO Sells $833,775.04 in Stock
07:08am, Friday, 20'th Feb 2026
Disc Medicine, Inc. (NASDAQ: IRON - Get Free Report) CEO John Quisel sold 13,264 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
08:06pm, Thursday, 19'th Feb 2026
NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised to c
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
04:58pm, Tuesday, 17'th Feb 2026
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. (“Disc” or the “Company”) (NASDAQ: IRON). Such investors are adv
Disc Medicine, Inc. (IRON) Discusses FDA Complete Response Letter and Path Forward for Bitopertin Regulatory Approval Transcript
04:34pm, Tuesday, 17'th Feb 2026
Disc Medicine, Inc. (IRON) Discusses FDA Complete Response Letter and Path Forward for Bitopertin Regulatory Approval Transcript
Disc Medicine to pursue traditional U.S. approval after FDA rejects new fast-track route
08:43am, Tuesday, 17'th Feb 2026
Disc Medicine said on Tuesday it will pursue a traditional U.S. approval pathway for its rare disease drug after the Food and Drug Administration declined to approve the treatment under a new fast-tra
FDA Delays Disc Medicine's Rare Disease Drug
05:54am, Tuesday, 17'th Feb 2026
Disc Medicine stock plunged after an FDA rejection of its rare disease drug but rebounded as investors weigh next steps.
US FDA declines to approve Disc Medicine's rare disease drug
03:12pm, Friday, 13'th Feb 2026
Disc Medicine said on Friday the U.S. Food and Drug Administration has declined to approve its drug to treat a rare genetic disorder, sending its shares down 31.6% to $48.90.
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP
03:04pm, Friday, 13'th Feb 2026
WATERTOWN, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
06:51pm, Thursday, 12'th Feb 2026
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised to con
